Rheumatology

Article	Citations
Granulomatosis with polyangiitis presenting as obstructive uropathy and vasculitic myopathy	203
Comment on: Switching from prednisolone to dexamethasone in difficult-to-treat rheumatoid arthritis	96
Comment on: Increased risk of osteoporosis and femoral neck fractures in patients with familial Mediterranean fever—a large retrospective cohort study	89
Comment on: AI am a rheumatologist: a practical primer to large language models for rheumatologists: reply	88
Boxer’s shape, an unusual finding in nailfold capillaroscopy	81
Comment on: The association between autoantibodies and risk for venous thromboembolic events among patients with rheumatoid arthritis: reply	71
Correction to: Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis	71
Prosthetic infections following tocilizumab treatment in patients with rheumatoid arthritis	69
Comment on: Predictors of lack of response to methotrexate in juvenile idiopathic arthritis–associated uveitis	68
E44 Differences of hematological abnormalities between COVID-19 infection and multisystemic inflammatory syndrome (MIS-C)	66
P011 Rituximab and COVID-19 vaccines; are they fit for purpose?	64
P042 Using a Genetic PROBability tool (G-PROB) to aid diagnosis of patients with inflammatory arthritis: results from the Norfolk Arthritis Register	63
29 Juvenile idiopathic arthritis and osteogenesis imperfecta: an exceptional association	60
67 Double impact: hypophosphatemic rickets and vitamin D intoxication	59
P114 Medication adherence to b/tsDMARDS remains sub-optimal in refractory rheumatoid arthritis	57
P173 The positive utility of PSAID-12 score in remote monitoring and the impact of gender and treatment on patient reported outcomes in psoriatic arthritis	55
E046 Lytic lesions; metastatic disease or gout?	54
P073 Functional investigation of Osteoarthritis-associated non-coding variants using CRISPR/Cas9-mediated perturbation of active enhancer regions	53
P058 Pneumocystis Jirovecii Infection in autoimmune inflammatory rheumatic diseases in Oxford	53
P107 Long-term efficacy of baricitinib in patients with rheumatoid arthritis with inadequate response to bDMARDs: results from RA-BEYOND up to 6.9-years of treatment	52
P041 Successful reversal of microvascular damage with standard therapy in a case of dermatomyositis overlap syndrome	51
E051 Audit of the management of patients over 75 with osteoporotic fragility fractures in primary care	51
P043 Income-Related Health Inequality and Osteoarthritis Intervention Outcomes: a Cohort Study	50
P110 Challenges of meeting NICE guidance for rheumatoid arthritis in the modern era: a service audit	48
E078 Inflammation modifies the effect of rheumatoid arthritis in overall mortality among females	47

26 Kawasaki’s disease vs systemic juvenile idiopathic arthritis, a diagnostic dilemma	47
P004 Empowering the reproductive choices of patients with rheumatic disease: using the BSR 2022 pregnancy guidelines audit tool to evaluate pre-conception medication advice	46
Comment on: Associations between loneliness, disease activity, and disease impact in inflammatory arthritis: a nationwide cross-sectional study among more than 12 000 patients	45
OA12 An update on the integrated safety analysis of filgotinib in patients with moderate to severe active rheumatoid arthritis over a median of 4.3 years	44
P133 Experiences of people with digital ulcers through filmed interviews	44
P004 Temporal and regional variation in the initiation of biologic and targeted synthetic DMARDs for rheumatoid arthritis: a nationwide cohort study	44
P193 Bimekizumab improves key symptoms, disease activity and function in patients across the full spectrum of axial spondyloarthritis up to week 24: results from two phase 3 studies	43
P174 Identifying patterns of fatigue across flares in patients with axial spondyloarthritis	43
P104 The role of occupational therapy for the self-management of rheumatoid arthritis: a mixed methods systematic review	42
54 Kawasaki disease: experience in a general paediatric department of the CHU de Annaba Algeria	42
OA22 Methotrexate drug monitoring and referral patterns to Hepatology - can we improve detection and monitoring of hepatoxicity with methotrexate use?	41
Bezoar secondary to NSAID use in a patient with inflammatory arthritis	40
The top 10 research priorities in psoriatic arthritis: a James Lind Alliance Priority Setting Partnership	39
A case of carpal tunnel syndrome caused by gouty tophi confirmed by dual-source CT	39
Bullous periorbital oedema in anti-p155/140-positive dermatomyositis: a case series	39
Giant cell arteritis of the prostate	39
Comment on: Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis—caution is key in interpreting retrospective data: Reply	38
Gastrointestinal manifestations in systemic lupus erythematosus: data from an Indian multi-institutional inception (INSPIRE) cohort	38
The usefulness of ultrasound in predicting outcomes in patients with shoulder pain: a prospective observational study	37
Transient osteoporosis of the hip: a novel vascular manifestation of COVID-19?	37
Soluble BDCA-2 as a potential biomarker for rheumatoid arthritis and its role in enhancing IFN-α production through nucleic acid binding	37
Real-world data on treatment persistence and measures to minimize cardiovascular risk in rheumatic patients using upadacitinib	37
Identification and characteristics of patients with axial psoriatic arthritis: clinical, phenotypic and imaging associations	36
P122 CCN3-derived peptide BLR-200 attenuates skin fibrosis by preventing activation of engrailed-1/COL8A1-expressing universal fibroblasts	35
P076 Paediatric rheumatology prescribing data: findings and recommendations from the Getting it Right First Time (GIRFT) report	35
P015 Interleukin-17 inhibitors rescue therapy in checkpoint inhibitor-associated adverse events: the state of play in 2025	35
OA20 Implementing a rheumatology advice and guidance pathway: improving patient access, supporting PIFU and optimising MDT workload	35
E083 Creation of a National Co-Development Hub for digital health interventions in chronic pain	34
P144 Defining a “flare”: a mixed methods exploration of patients’ and clinicians’ perspectives in systemic lupus erythematosus and other systemic autoimmune rheumatic diseases	34
OA29 Developing the UK Rheumatology Occupational Therapy Capabilities Framework: A national co-produced initiative	34
P050 Mapping reproductive services in UK rheumatology: unmet needs in menopause, fertility, and male reproductive health	34
OA03 Serum proteome profiling reveals candidate biomarkers for paediatric chronic nonbacterial osteomyelitis	34
E074 Diagnostic coding in outpatient paediatric rheumatology: insights from the Getting It Right First Time programme	33
P190 Structures of proteinase 3 and the CD177 receptor complex reveals major autoantibody epitope	33
Human dermal fibroblast-derived exosomes induce macrophage activation in systemic sclerosis	32
E135 Real-world effectiveness and safety of belimumab in lupus nephritis: first 12-month cohort experience from Central Asia (2024-2025)	32
Neither ultrasound synovitis nor clinical-ultrasound phenotypes of established rheumatoid arthritis predict response to targeted therapy	32
E144 Using social media data to understand the lived experience of people with psoriatic arthritis receiving biologic therapies and weight management interventions	32
P003 Molecular mechanisms in chronic nonbacterial osteomyelitis and their therapeutic potential	32
Anti-nuclear valosin-containing protein-like autoantibody is associated with calcinosis and higher risk of cancer in systemic sclerosis	32
E080 Do individual or area-level measurements of social determinants of health perform better at predicting chronic pain?	32
Menstruation in adolescents with familial Mediterranean fever: attack trigger or dysmenorrhoea? A prospective cross-sectional study	31
Combined radiographic and US evaluations to decipher joint involvement in the hands of patients with SSc	31
Comparative risk of blindness and vision-threatening ocular comorbidities in patients with Behçet’s disease versus the general population	31
Genetics of longitudinal kidney function in children and adults with systemic lupus erythematosus	31
Comment on: Key factors contributing to gender inequity in global rheumatology awards: a global survey analysis: reply	31
Can we use patient-reported outcomes for remote monitoring in SSc?	30
Will we ever agree on using low-dose glucocorticoids in treating rheumatoid arthritis?	30
Negative back beliefs are associated with increased odds of low back pain and disability: a 10-year cohort study in men	30
A child with CANDLE syndrome presenting as seronegative polyarthritis following early chemotherapy	30

Prodromal symptoms of rheumatoid arthritis in a primary care database: variation by ethnicity and socioeconomic status	30
Comment on: Impact of baseline proteinuria level on long-term outcomes in lupus nephritis	30
Clinician views concerning the prevalence and impact of granulomas on the diagnosis, management, and outcomes of ANCA-associated vasculitis	30
Central retinal vein and cilioretinal artery occlusion in a case of systemic sclerosis treated with a JAK inhibitor figlotinib	30
Risk of major organ involvement in Behçet’s patients with mucocutaneous onset: data from the AIDA Network Registry	30
Reliability of ultrasound assessment of elementary lesions in psoriatic arthritis and development of a reference dactylitis atlas	29
A rare JAK2 mutation associated with adult-onset Still’s disease and exacerbated vaccine-induced innate immune response	29
The state of data sharing in rheumatology: a systematic review of top journal practices	29
Effectiveness of intravenous infliximab versus subcutaneous adalimumab in Takayasu arteritis: multicenter retrospective study	29
Biopsy vs imaging for the diagnosis of giant cell arteritis. Viewpoint 2: in favour of biopsy	29
Impaired humoral and T helper cell responses to toxic shock syndrome toxin-1 (TSST-1) in granulomatosis with polyangiitis	29
Development of a time-dependent prediction model for the risk of Pneumocystis jirovecii pneumonia in ANCA-associated vasculitis	29
Advances in the diagnosis of myocarditis in idiopathic inflammatory myopathies: an overview of diagnostic tests	28
IGFBP5 regulates fibrocartilage differentiation and cartilage injury induced by T-2 toxin via blocking IGF-1/IGF-1R signalling	28
Efficacy of the Lupus-Cruces Nephritis protocol in different prognostic groups: a propensity score and cluster analysis	28
Renal outcomes in ANCA-associated vasculitis without clinically apparent kidney involvement: a multicentre REVEAL cohort study	28
Validation of a questionnaire for central nervous system aspects of joint pain: the CAP questionnaire	28
Targeting fibroblasts in immune mediated inflammatory diseases: a cellular basis for cure?	28
Oesophageal dysmotility patterns are associated with distinct clinical phenotypes and prognosis in patients with systemic sclerosis	28
Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE	28
Improvement of high-density lipoprotein atheroprotective properties in patients with systemic lupus erythematosus after belimumab treatment	27
Lymphocyte subset phenotyping for the prediction of progression to inflammatory arthritis in anti-citrullinated-peptide antibody-positive at-risk individuals	27
The impact of traditional cardiovascular risk factor control on 7-year follow-up atherosclerosis progression in systemic lupus erythematosus	27
The efficacy of rituximab plus belimumab or telitacicept in refractory lupus nephritis	27
Sensorineural hearing loss in anti-interleukin-1 treated CAPS patients: risk factors and real-life barriers—an observational study	26
A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis	26
Targeting axial and peripheral psoriatic arthritis: a retrospective observational study on the clinical relevance of upadacitinib	26
Enhancing diagnosis of gout with deep learning in dual-energy computed tomography: a retrospective analysis of crystal and artefact differentiation	26
Identification of circulating microRNA patterns in patients in psoriasis and psoriatic arthritis	26
The influence of biological DMARDs on aseptic arthroplasty loosening: a retrospective cohort study	26
Avacopan may not independently reduce ANCA titres in ANCA-associated vasculitis: a retrospective analysis of 57 patients	26
Factors associated with delay in the diagnosis and treatment of systemic lupus erythematosus in adult patients: a systematic review	26
Anti-SARS-CoV-2 vaccination in adolescent and adult patients with juvenile-onset systemic lupus erythematosus: tolerability and impact on disease activity	26
Plasma proteomics for risk prediction and identification of novel drug targets in systemic lupus erythematosus	26
A systematic review of patient-reported outcome measures in patients with anti-neutrophil cytoplasmic antibody associated vasculitis	26
VEXAS syndrome mimicking lupus-like disease	26
Stability and prognostic value of B-cell markers in primary SS: results from the French ASSESS cohort	26
Effects of interleukin-6 signal inhibition on Treg subpopulations and association of Tregs with clinical outcomes in rheumatoid arthritis	26
Ixekizumab-associated disseminated tinea corporis in a patient with psoriatic arthritis and plaque psoriasis	25
High levels of EPSTI1 enhance IFN-β-mediated HLA-A expression and chemokine secretion in myoblasts in dermatomyositis	25
Plasma metabolomics and incident major adverse cardiovascular events in patients with rheumatoid arthritis	25
Lupus serology: off target but still relevant to the treat-to-target strategy in systemic lupus erythematosus	25
Relapses and serious adverse events during rituximab maintenance therapy in ANCA-associated vasculitis: a multicentre retrospective study	25
Correction to: TLR8 aggravates skin inflammation and fibrosis by activating skin fibroblasts in systemic sclerosis	25
Cardiac involvement in systemic sclerosis: mechanisms, manifestations and management	25
Type I interferon dysregulation drives distinct pathogenic pathways in early- and late-onset lupus nephritis	25
Ex vivo cell-based assay for assessment of response to TNF inhibitors in patients with rheumatic diseases	24
P208 PET-CT scanning of GCA patients: the additive role of opportunistic screening for cardiovascular disease in a high-risk population	24
P110 Characteristics of Difficult to treat Rheumatoid Arthritis patients in a large District Hospital in the UK	24
Comment on: Comparing clinical features between males and females with VEXAS syndrome: data from literature analysis of patient reports	24
E68 Kawasaki Disease before and during COVID-19	24
E71 Distribution of cells and extracellular matrix in the normal marginal synovium of the hip joint capsule during the postnatal period	24
Giant thymic cyst overclouding the diagnosis of fibrodysplasia ossificans progressiva: an inconvenient coincidence	24
P133 Attitudes to Technology supported Rheumatoid Arthritis care: Opportunities & Barriers for technology in RA - Key themes from Qualitative arm of Mixed-Methods Study	24
P027 Infliximab in the treatment of cerebral tuberculosis paradoxical reactions with vasculitis	24
20 Does hip involvement affect foot and ankle in juvenile idiopathic arthritis?	23
OA28 VEXAS, a service evaluation in Rheumatology at Sheffield: “Seek, and ye shall find”	23
P012 Pneumocystis jirovecii pneumonia in rheumatology patients - a single centre ten-year audit	23
E001 Pre-screen chest X-ray before starting methotrexate in autoimmune disease	23
64 Conical teeth? Think outside the box!	23
P055 Gabapentinoid use and the risk of fractures in patients with inflammatory arthritis: nested case-control study in the Clinical Practice Research Datalink Aurum	23
61 The nailfold videocapillaroscopy in pediatric Behçet’s disease: a multi-center study	23
E005 An audit of demographics, symptoms & investigations: Part of the survey of GCA in the SEHSCT during the COVID-19 pandemic	23
P046 The influence of deprivation in the outcomes of Psoriatic Arthritis within the UK - utilising Outcomes of Treatment in Psoriatic Arthritis Study Syndicate data	23
P038 The importance of looking carefully for the cause(s)	23
E005 Investigation into the post-diagnostic care and follow-up of patients with giant cell arteritis post-initiation of long-term glucocorticoids at University Hospitals Leicester NHS Foundation Trust	23
56 Prevalence and severity of infections in patients with systemic autoimmune diseases on biotherapy	23
Performance of the 2016 ACR-EULAR Myositis Response Criteria in adult dermatomyositis/polymyositis therapeutic trials and consensus profiles	22
77 Case series of juvenile scleroderma from Nigeria	22
P127 A retrospective cohort study assessing outcomes and safety in patients receiving low dose vs high dose cyclophosphamide in myositis interstitial lung disease	22
Correction to: Association of serum interferon alpha-2a levels with disease severity and prognosis in systemic sclerosis	22
P081 Is it necessary to test vitamin D prior to zoledronate or denosumab treatment?	22
Evaluation of patient-based disease activity score (PDAS) in the Japanese rheumatoid arthritis patient registry (NinJa registry)	22
Incidence and predictors of demyelinating disease in spondyloarthritis: data from a longitudinal cohort study	22
P117 Remote monitoring of rheumatoid arthritis using RAPID3 to support patient-initiated follow up	22
Risk of venous thromboembolism in people with RA: a population-based study in the UK	22
Correction to: Non-adherence to urate lowering therapy in gout after 5 years is related to poor outcomes: results from the NOR-Gout study	22
Comment on: Prevalence, distribution and associations of the scleroderma capillaroscopic patterns: new insights from the Italian SPRING-SIR registry: Reply	22
P094 Experts in lived experience: CLUSTER Champions and their successful collaboration in JIA research	22
Assessing the role of climate and the environment as co-factors for vasculitis diseases	22

COVID-19 vaccination in autoimmune diseases (COVAD) study: vaccine safety and tolerance in rheumatoid arthritis	22
Comment on: Systemic lupus erythematosus patients have unique changes in serum metabolic profiles across age associated with cardiometabolic risk: reply	21
Comment on: Comparable 12-month renal response outcomes with medium- vs high-dose starting prednisone in a real-world study of lupus nephritis	21
Identification and functional characterization of urinary protein biomarkers for RA	21
Fine particulate matter air pollution and anti-nuclear antibodies	21
Comment on: Comparable 12-month renal response outcomes with medium- vs high-dose starting prednisone in a real-world study of lupus nephritis: reply	21
Treating rheumatoid arthritis to target in pregnancy	21
Raynaud’s phenomenon and digital ischaemia induced by ixekizumab	21
A case of hypertrophic pachymeningitis with neutrophil extracellular traps formation	21
Interstitial lung disease in limited cutaneous systemic sclerosis patients: never let your guard down	21
Optimal exposure of mycophenolic acid for induction therapy of childhood lupus nephritis patients: an observational cohort study	20
E044 Telephone clinic consultations in the COVID-19 era: the rates of conversion to face-to-face appointments and discharges in the post-pandemic years	20
E042 The role of intra-articular steroid treatment for osteoarticular tuberculous paradoxical reactions of the knee: a report of two cases at Sheffield Teaching Hospitals	20
P156 Type I interferon is raised across connective tissue diseases and is associated with haematological abnormalities and specific autoantibody profiles	20
P066 Systematic review of the clinical effectiveness of Tixagevimab/Cilgavimab for prophylaxis of COVID-19 in immunocompromised patients	20
Five-year cardiovascular event risk in early rheumatoid arthritis patients who received treat-to-target management: a case-control study	20
P010 Idiopathic recurrent pericarditis: an inflammatory affair between Cardiology and Rheumatology	20
Successful switching from mepolizumab to dupilumab in a patient with EGPA in remission phase and persistent nasal polyposis	20
OA08 JAK inhibitors and the risk of malignancy: a meta-analysis across licenced disease indications	20
P039 Haemophagocytic lymphohistiocytosis secondary to invasive aspergillosis in a patient with undiagnosed SLE	20
P106 Feasibility Study of Methotrexate use Improvement in Rheumatoid Arthritis using Biomarker Feedback: The MIRA Trial	20
P123 Biologic dose tapering: a patient perspective	20
P018 The double-edged sword: weighing methotrexate’s benefits against hepatic toxicity - a study to assess long term safety of methotrexate	20
E048 A review of published data on reported staffing ratios for rheumatology specialist physiotherapists in rheumatology departments	20
E150 Variation in axial spondyloarthritis service provision across London: findings from a regional network survey	20
P133 Anti-synthetase syndrome: an experience from a tertiary referral center	20
P113 Cellular profiling of synovial fluid in inflammatory arthritis highlights disease-specific cell states with biological and diagnostic relevance	20
E29 Juvenile Idiopathic Arthritis (JIA) in Algeria, from diagnosis to management	20
Correction to: Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region	20
E104 The interaction between methotrexate and proton pump inhibitors: a systematic literature review	20
OA36 Paediatric rheumatology and health inequalities: findings and recommendations from the Getting it Right First Time (GIRFT) report	19
P007 Oral Janus kinase inhibitor upadacitinib effective in refractory multisystem SAPHO syndrome with dissecting cellulitis	19
E050 Parathyroidectomy vs pharmacological strategies in the management of bone health in patients with primary hyperparathyroidism: a service improvement audit	19
Avacopan in an ocular complication of ANCA-PR3 vasculitis without kidney involvement	19
Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-responders	19
P023 Validation of a 14-3-3η autoantibody assay combined with CRP and HLA-B27 to improve axial spondyloarthritis detection	19
P028 Musculoskeletal ultrasound in rheumatology vs radiology: a comparative service evaluation	19
Emerging targeted therapies in ANCA-associated vasculitis	19
RETRACTED: Multicentric Castleman disease presenting with frequent urination	19
Nailfold videocapillaroscopy findings correlate with lung outcomes in idiopathic inflammatory myopathies–related interstitial lung disease	19
E122 Accuracy of diagnostic codes and algorithms used to identify connective tissue diseases in electronic health records: a systematic review	19
P070 Unmasking an autoimmune breast disease: rheumatology’s evolving role in idiopathic granulomatous mastitis	19
P172 Weight management and GLP-1 receptor agonists in psoriatic disease: insights from a survey of rheumatology and dermatology professionals	19
Citrate in the management of gout, urate nephrolithiasis and kidney disease: an old therapy rediscovered?	19
Predicting treatment response to methotrexate: are we closer to solving the enigma?	19
Treating-to-target: remission and low disease activity in systemic lupus erythematosus versus rheumatoid arthritis	18
Addressing the unmet needs of transitional care in juvenile idiopathic arthritis	18
Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate	18
IFN-α levels correlate with muscle disease activity only in juvenile dermatomyositis patients with anti-MDA5+ autoantibodies	18
Opinions on contributing data to research studies: survey results from adults living with juvenile idiopathic arthritis (JIA)	18
Upadacitinib in the treatment of Takayasu arteritis: a case report on new perspectives on targeted immunomodulation	18
Increased risk of myocarditis and arrythmias in anti-Ku-positive scleroderma–myositis overlap patients: a case series	18
Urological cancer risk in patients with rheumatoid arthritis compared to matched controls: a nationwide cohort study	18
Where are we now in biologic drugs for myositis?	18
HLA-C*06–defined endotype in psoriatic disease: an ever-widening landscape	18
Neutrophil-to-lymphocyte ratio as a biomarker for disease onset and mortality risk in SSc: a real-world national cohort study	18
Highlights from the plenary session: eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome	18
Gastrointestinal involvement in very early and established systemic sclerosis: insights from the SPRING-SIR national Italian registry	18
Automated high-resolution CT analysis outperforms visual assessment in predicting interstitial lung disease progression in SSc	18
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease	18
Comment on: Exploring the effects of GLP-1 receptor agonists in fibromyalgia: a propensity-matched real-world cohort using the TriNetX research platform: reply	18
Comment on: risk of urinary tract infections associated with SGLT2 inhibitor use in patients with rheumatoid arthritis: a target trial emulation study: reply	18
Correction to: Ten-year cardiovascular risk changes and major adverse events in gout patients	18
Glucocorticoids rarely required in granulocyte colony-stimulating factor-associated large-vessel vasculitis: Japanese cancer centre cohort	18
P139 Impact of hand function impairment on daily life of patients with systemic sclerosis - a qualitative study	18
Step-down treatment with mepolizumab for eosinophilic granulomatosis with polyangiitis: a real-life single-centre study	18
Factors associated with anakinra effectiveness and risk of infection in crystal-related flares	18
Patient burden and joint inflammation during development of RA from arthralgia: is it similar in ACPA-positive and ACPA-negative disease?	18
OA01 Cluster medicine: the role of genetics for identifying shared biological pathways between rheumatoid arthritis and common comorbidities for targeting treatments	18
Antibody predictors of mortality and lung function trends in myositis spectrum interstitial lung disease	18
A multivariable prediction model to identify anti-CCP positive people in those with non-specific musculoskeletal symptoms in primary care	18
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease	17
Sarcoid myopathy: an insidious diagnosis that can mimic inclusion body myositis	17
Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis	17
Does plasma exchange have a role in ANCA-associated vasculitis? Viewpoint 2: plasma exchange may be useful under some circumstances	17
OA35 Amplifying young voices: the crucial role of young people living with rheumatic conditions in shaping information, advice and guidance	17
E007 Is there an urgent need to change the methotrexate monitoring guidelines to incorporate fibroscan?	17
E34 Coexisting sickle cell disease and autoimmune diseases among Nigerian children	17
Teledidactic peer-tutored musculoskeletal ultrasound training for medical students—the TELMUS study	17
Physical activity in relation to the risk of systemic lupus erythematosus: a prospective study including 401 745 individuals	17
Experience with upadacitinib in refractory polyarticular juvenile idiopathic arthritis	17
Free IL-18 in NLRC4-associated autoinflammatory disease without macrophage activation syndrome	17
E047 I felt like I’d been given a new lease of life: Exploring the information needs and experiences of people with rheumatoid arthritis receiving bridging glucocorticoids when starting methotrexate	17
P069 Moving more with Axial Spondyloarthritis - a short survey to help design future exercise studies	17
P191 Efficacy and improvement in patient-reported outcomes at weeks 16 and 52 in ixekizumab treated biological naïve patients with radiographic axial spondyloarthritis achieving clinically important p	17
Unforeseen complication in juvenile dermatomyositis	17
Effectiveness of pharmacological therapies for fibromyalgia syndrome in adults: an overview of Cochrane Reviews	17
Cancer risk with tocilizumab/sarilumab, abatacept and rituximab treatment in patients with rheumatoid arthritis: a Danish cohort study	17
Is the relationship between deprivation and outcomes in rheumatoid arthritis mediated by body mass index? A longitudinal cohort study	17
Use of sarilumab in VEXAS syndrome	17
E26 Macrophage activation syndrome in systemic juvenile idiopathic arthritis, one centre experience	17
P200 Re-validation of the use of Giant Cell Arteritis Probability Score (GCAPS) in daily practice to risk stratify GCA referrals: experience from a United Kingdom fast track clinic	17
E45 Kawasaki syndrome-related heart disease before and during the COVID-19 pandemic	17
Progressive interstitial lung disease associated with rheumatoid arthritis and abatacept: data from a multicentre cohort of 526 patients	16
P076 Beyond articular cartilage: a systematic review of the extracellular matrix in other components of the osteoarthritic joint	16